MSD Merck Sharp

Company snapshot

MSD Merck Sharp maintains 217 tracked programs across Atherosclerosis, Non-small Cell Lung Cancer (NSCLC), Hypercholesterolemia, HIV infection, Acute and chronic Pain, Rheumatoid arthritis, Pain, Advanced Solid Tumors, Hormone receptor positive breast cancer, Gastroesophageal cancer, Metastatic castration resistant prostate cancer, Advanced Urothelial Carcinoma. Momentum score: n/a/100 (30-day del

• 217 active pipeline program(s) linked via ClinicalTrials.gov.
• 217 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for MSD Merck Sharp. Not investment advice.

• Peer + 0 momentum

  Cumberland Pharmaceuticals

  TA overlap score 30.6

• Peer + 0 momentum

  Revolution Medicines

  TA overlap score 25.2

Recent activity

Latest pipeline, patent, and corporate events for MSD Merck Sharp.

1. Jun 8, 2026 Clinical update

   MS201924_0003 — Phase 1

2. Jun 8, 2026 Clinical update

   MK-3475A-F11 — Phase 2

3. Jun 8, 2026 Clinical update

   MK-3475-905 — Phase 3

4. Jun 8, 2026 Clinical update

   V940-007 — Phase 3

5. Jun 8, 2026 Clinical update

   MS200569_0065 — Phase 1

View all clinical trial activity →

• What is MSD Merck Sharp?

  Merck Sharp and is a pharma organization headquartered in EU. Primary therapeutic focus areas include Atherosclerosis, Non-small Cell Lung Cancer (NSCLC), Hypercholesterolemia, HIV infection, Acute and chronic Pain. NovaPharmaNews links 217 clinical program(s), 0 drug profile(s),

• Is MSD Merck Sharp publicly traded?

  MSD Merck Sharp appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does MSD Merck Sharp develop or market?

  We link 180 drug profile(s) where MSD Merck Sharp is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/merck-sharp-and-dohme#company-drugs.

• What are the latest developments for MSD Merck Sharp?

  In the last 12 months our linked public records show 217 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does MSD Merck Sharp focus on?

  MSD Merck Sharp focuses on Atherosclerosis, Non-small Cell Lung Cancer (NSCLC), Hypercholesterolemia based on our analysis of their pipeline programs and drug development activities.